{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:49:49Z","timestamp":1780606189245,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Myasthenia gravis is an organ-specific autoimmune disease. Currently there is no universal guidelines for childhood-onset myasthenia gravis, therefore, treatment strategies are usually based on the guidelines from adult myasthenia gravis patients. In order to contribute in the process of the development of the universal childhood-onset myasthenia gravis guideline, we have summarized the clinical characteristics, treatment strategies, outcome and the related predictors of childhood-onset myasthenia gravis. We recruited 343 childhood-onset myasthenia gravis cases who were followed up at the Department of Pediatrics, Xiangya Hospital from June, 2010 to December, 2019. The data about clinical characteristics, treatments and outcome were collected and analyzed. Among of the 343 cases, 164 cases were followed up for longer than 2 years, of whom 142 still remained with ocular myasthenia gravis at the endpoint. About the treatments, 27 cases (27\/164) accepted pyridostigmine only while the rest accepted glucocorticoid and\/or other immunosuppressants. At the endpoint, the proportion of optimal outcome was 66.2% in the group remaining with ocular myasthenia gravis and 31.8% in the generalized myasthenia gravis group. Multivariate logistic regression analysis revealed that generalized myasthenia gravis type and positive status of antibodies against acetylcholine receptors were the independent risk factors for poor outcome. In conclusion, our childhood-onset myasthenia gravis patients present mainly as ocular myasthenia gravis, adequate immunotherapy improve the long-term outcome, and generalized myasthenia gravis phenotype as well as positive status of antibodies against acetylcholine receptors relate to poor outcome.<\/jats:p>","DOI":"10.3389\/fped.2022.996213","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T11:45:07Z","timestamp":1664451907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort"],"prefix":"10.3389","volume":"10","author":[{"given":"Lifen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","article-title":"Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Paediatric myasthenia gravis: prognostic factors for drug free remission","volume":"30","author":"Vecchio","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","article-title":"Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort","volume":"87","author":"Vanikieti","year":"2018","journal-title":"Pediatr Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui","year":"2015","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0883073816666206","article-title":"Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age","volume":"31","author":"Lee","year":"2016","journal-title":"J Child Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.braindev.2011.12.014","article-title":"Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course","volume":"34","author":"Takahashi","year":"2012","journal-title":"Brain Dev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mus.25965","article-title":"Clinical features and evolution of juvenile myasthenia gravis in a French cohort","volume":"57","author":"Barraud","year":"2018","journal-title":"Muscle Nerve"},{"key":"B11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in Southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3892\/etm.2015.2256","article-title":"Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis","volume":"9","author":"Yang","year":"2015","journal-title":"Exp Ther Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1179\/1465328111Y.0000000042","article-title":"Myasthenia gravis in Jamaican children: a 12-year institutional review","volume":"32","author":"Melbourne Chambers","year":"2012","journal-title":"Paediatr Int Child Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.11817\/j.issn.1672-7347.2017.11.006","article-title":"[Analysis for the effect of different regimens on ocular myasthenia gravis in children]","volume":"42","author":"Liu","year":"2017","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"B18","doi-asserted-by":"publisher","first-page":"116740","DOI":"10.1016\/j.jns.2020.116740","article-title":"Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis","volume":"412","author":"Sugimoto","year":"2020","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.996213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T11:45:10Z","timestamp":1664451910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.996213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":19,"alternative-id":["10.3389\/fped.2022.996213"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.996213","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"996213"}}